托法替布剂量递减治疗中重度溃疡性结肠炎的真实世界经验
该真实世界队列纳入162例中重度溃疡性结肠炎成人患者,52%维持10 mg每日两次,48%递减至5 mg每日两次;12个月UC事件累积发生率在递减与未递减组相似(56% vs 58%;P = .81)。递减组中诱导疗程超过16周对UC事件有保护作用(HR 0.37;95% CI 0.16-0.85),持续严重疾病(Mayo 3)与UC事件相关(调整后HR 6.05;95% CI 2.00-18.35)。
要点
- 托法替布剂量递减至5 mg每日两次与维持10 mg每日两次的12个月UC事件累积发生率相似(56% vs 58%;P = .81)。
- 递减组中诱导疗程超过16周对UC事件有保护作用(HR 0.37;95% CI 0.16-0.85)。
- 递减组中持续严重疾病(Mayo 3)与UC事件相关(调整后HR 6.05;95% CI 2.00-18.35)。
核心结论
- 在该真实世界队列中,托法替布剂量递减患者12个月UC事件累积发生率为56%。
- 剂量递减后UC事件相关因素包括诱导疗程少于16周和开始治疗后6个月时活动性内镜下病变。
研究设计与样本
- 纳入2012年6月至2022年1月期间接受托法替布治疗的中重度UC成人患者162例。
- 主要结局为UC疾病活动相关事件:住院/手术、开始皮质类固醇、托法替布剂量增加或治疗转换。
主要发现
- 162例患者中52%继续10 mg每日两次,48%剂量递减至5 mg每日两次。
- 12个月UC事件累积发生率在递减与未递减组相似(56% vs 58%;P = .81)。
- 递减组单变量Cox回归中,诱导疗程10 mg每日两次超过16周对UC事件有保护作用(HR 0.37;95% CI 0.16-0.85)。
- 递减组中持续严重疾病(Mayo 3)与UC事件相关(HR 6.41;95% CI 2.23-18.44),调整年龄、性别、诱导疗程时长和递减时皮质类固醇使用后仍显著(HR 6.05;95% CI 2.00-18.35)。
- 发生UC事件的患者中29%将剂量重新增至10 mg每日两次,仅63%在12个月时能重获临床应答。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Tofacitinib is associated with sustained steroid-free remission in patients with ulcerative colitis (UC), with the lowest effective dose recommended for maintenance therapy. However, there are limited real-world data to guide decisions on the optimal maintenance regimen. We aimed to evaluate predictors and outcomes of disease activity after tofacitinib dose de-escalation in this population. METHODS: Included were adults with moderate-severe UC treated with tofacitinib between June 2012 and January 2022. The primary outcome was evidence of UC disease activity-related events: hospitalization/surgery, corticosteroid initiation, tofacitinib dose increase, or therapy switch. RESULTS: Among 162 patients, 52% continued 10 mg twice daily while 48% underwent dose de-escalation to 5 mg twice daily. Cumulative incidence rates of UC events at 12 months were similar in patients with and without dose de-escalation (56% vs 58%; P = .81). In univariable Cox regression among patients with dose de-escalation, an induction course with 10 mg twice daily for more than 16 weeks was protective of UC events (hazard ratio [HR], 0.37; 95% CI, 0.16-0.85) while ongoing severe disease (Mayo 3) was associated with UC events (HR, 6.41; 95% 95% CI, 2.23-18.44), which remained significant after adjusting for age, sex, duration of induction course, and corticosteroid use at dose de-escalation (HR, 6.05; 95% CI, 2.00-18.35). Twenty-nine percent of patients with UC events had their dose re-escalated to 10 mg twice daily, with only 63% able to recapture clinical response at 12 months. CONCLUSIONS: In this real-world cohort, we observed a 56% cumulative incidence of UC events at 12 months in patients with tofacitinib dose de-escalation. Observed factors associated with UC events after dose de-escalation included induction course for fewer than 16 weeks and active endoscopic disease 6 months after initiation.
引用
- Yu A, Ha NB, Shi B, et al. Real-World Experience With Tofacitinib Dose De-Escalation in Patients With Moderate and Severe Ulcerative Colitis. Clin Gastroenterol Hepatol. 2023. PMID: 37187323. doi:10.1016/j.cgh.2023.05.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。